

September 2, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 BSE Scrip Code: 500067	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 NSE Symbol: BLUESTARCO
--	---

Dear Sir/Madam,

Sub.: Update on completion of sale and transfer of MedTech business of Blue Star Engineering & Electronics Limited, a wholly owned subsidiary of the Company

We refer to our letter dated August 14, 2026 (enclosed), wherein we had intimated about the execution of a Business Transfer Agreement ('BTA') by Blue Star Engineering & Electronics Limited ('Blue Star E&E'), a wholly owned subsidiary of the Company, with Cyrix Healthcare Private Limited ('Cyrix') for the sale and transfer of Blue Star E&E's MedTech business, comprising the business of providing high-end medical diagnostic equipment and services, as a going concern on a slump sale basis.

In connection therewith, we hereby inform you that Medtech business of Blue Star E&E has been transferred to Cyrix effective September 1, 2026. The confirmation in this regard was acknowledged by Cyrix yesterday at 11.30 p.m.

The consideration is payable in tranches, subject to adjustments, if any, in accordance with the terms of the BTA, with the final tranche payable on March 31, 2027.

This is for your information and record.

The above information is also being placed on the website of the Company at www.bluestarindia.com



Blue Star Limited

Band Box House, 4th Floor,
254 D, Dr Annie Besant Road,
Worli, Mumbai 400 030, India.

T : +91 22 6654 4000

E : secretarialdesk@bluestarindia.com

www.bluestarindia.com

Thanking you,

Yours faithfully,
For **Blue Star Limited**



Rajesh Parte
Company Secretary & Compliance Officer
Membership No.: A10700

Encl: a/a

August 14, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 BSE Scrip Code: 500067	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 NSE Symbol: BLUESTARCO
--	---

Dear Sir/Madam,

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') – Execution of Business Transfer Agreement by Blue Star Engineering & Electronics Limited, a wholly owned subsidiary of the Company.

In compliance with Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations, we hereby inform you that the Board of Directors of the Blue Star Engineering & Electronics Limited ('Blue Star E&E'), a wholly owned subsidiary of the Company at its meeting held today i.e. Friday, August 14, 2026, has, *inter alia*, executed a Business Transfer Agreement ('BTA') with Cyrix Healthcare Private Limited ('Cyrix') for the sale and transfer of Blue Star E&E's MedTech division, comprising the business of providing high-end medical diagnostic equipment and services, as going concern on a slump sale basis, on such terms and conditions as detailed in the BTA.

The meeting of Blue Star E&E commenced at 6:15 p.m. and concluded at 6:45 p.m.

The details as required under Para A of Part A of Schedule III of the Listing Regulations and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (as amended) are enclosed as 'Annexure – I'.

The above information is also being placed on the website of the Company at www.bluestarindia.com

Kindly take the same on record.

Thanking you,

**Blue Star Limited**

Band Box House, 4th Floor,
254 D, Dr Annie Besant Road,
Worli, Mumbai 400 030, India.

T : +91 22 6654 4000

E : secretarialdesk@bluestarindia.com

www.bluestarindia.com

Yours faithfully,

For **Blue Star Limited**

RAJESH

DIGAMBAR

PARTE

Digitally signed by
RAJESH DIGAMBAR
PARTE

Date: 2026.08.14
20:49:52 +05'30'



Rajesh Parte

Company Secretary & Compliance Officer

Membership No.: A10700

Encl: a/a

ANNEXURE - I

**Details as required under the Listing Regulations read with SEBI Master Circular
No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

Sr. No.	Particulars	Description
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	The MedTech division of Blue Star E&E generated a total income of Rs 42.13 crores during the financial year ended March 31, 2026, representing approximately 0.33% of the Company's consolidated income from operations for the said year. As the MedTech division forms an integral part of the Blue Star E&E's overall business operations, its net worth is not maintained or reported separately. As per the audited consolidated financial statements of the Company for the year ended March 31, 2026, Blue Star E&E's MedTech division net worth is approximately Rs 7.11 crores as on March 31, 2026, constituting around 0.21% of the Company's net worth.
2.	Date on which the agreement for sale has been entered into;	August 14, 2026
3.	The expected date of completion of sale/disposal;	Slump Sale of MedTech division of Blue Star E&E is proposed to be completed by March 31, 2027, subject to satisfactory fulfilment of the conditions precedent, including obtaining all requisite approvals and completion of such procedures as may be required, in accordance with the terms of the BTA.
4.	Consideration received from such sale/disposal;	Upto Rs 40,00,00,000 (Rupees Forty Crores), as per the terms of the BTA.
5.	brief details of buyers and whether any of the buyers belong to the promoter/	Cyrix Healthcare Private Limited (Cyrix) is a leading, pan-India Total MedTech Management Solutions provider with over 22 years of industry

	promoter group/group companies. If yes, details thereof;	experience. Cyrix is not a part of the Promoter or Promoter Group of the Company.
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	This transaction does not fall within the ambit of related party transactions.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of Listing Regulations;	Yes, the transaction is outside the scope of the Scheme of Arrangement. The provisions of Regulation 37A of the SEBI Listing Regulations are not applicable to this transaction.
Additional disclosure in case of a Slump Sale		
8.	Name of the entity(is) forming part of the slump sale, details in brief such as, size, turnover etc.	Please refer to the details specified in point nos. (1) and (5) above.
9.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	This transaction does not fall within the ambit of related party transactions.
10.	Area of business of the entity(ices);	Seller: Blue Star Engineering & Electronics Limited (Blue Star E&E), a wholly-owned subsidiary of Blue Star Limited, is a leading provider of comprehensive engineering solutions in India. With decades of expertise, Blue Star E&E provides cutting-edge technology and turnkey solutions across Data Security, MedTech and Industrial Solutions. Buyer: Cyrix Healthcare Private Limited (Cyrix) is a leading, pan-India Total MedTech Management Solutions provider with over 22 years of industry experience.

11.	Rationale;	The Business Transfer is being undertaken to focus on strategic priorities.
12.	In case of cash consideration - amount or otherwise share exchange ratio;	Upto Rs 40,00,00,000 (Rupees Forty Crores), as per the terms of the BTA.
13.	Brief details of change in shareholding pattern (if any) listed entity;	Not applicable